JAK2 and myelofibrosis: Navitoclax had significant antitumor activity in patients with myelofibrosis in the phase 2 REFINE trial (NCT03222609) and is undergoing a phase 3, double-blind, placebo-controlled, multicenter, international study (TRANSFORM-1) evaluating its safety and efficacy in combination with ruxolitinib in JAK2 inhibitor-naïve adults with myelofibrosis [42,43].